In Vivo is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Girding For New GERD Therapies

Executive Summary

Two biotech companies, Addex Pharmaceuticals and XenoPort, are in a tight race to develop successors to the generic or soon-to-be-generic blockbuster proton pump inhibitors. As the firms' drugs proceed through clinical trials, their respective outcomes are an object lesson for biotechs and pharmaceutical companies looking to enter a crowded space already well served by existing medicines.
Advertisement

Related Content

XenoPort Gives Up On Reflux Drug After It Fails To Beat Placebo
Adventures in Glutamate: The Difficult and Expensive Path of Novelty in Drug Discovery
Adventures in Glutamate: The Difficult and Expensive Path of Novelty in Drug Discovery
AZ Joins Spin-Out Set, Forms GI Play Albireo
Pharma's R&D Heartburn Spells Opportunity for GI-Focused Biotechs
Pharma's R&D Heartburn Spells Opportunity for GI-Focused Biotechs

Topics

Related Companies

Related Deals

Advertisement
UsernamePublicRestriction

Register

IV003203

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel